Cicero、ILにおける非小細胞肺癌の臨床試験
Ciceroとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
被験者募集中第1/2相
- Hope And Healing Cancer Services /ID# 276223, Hinsdale · 10マイル先
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Edward Hines Jr VA Hospital, Hines · 4マイル先
- Advocate Christ Medical Center, Oak Lawn · 9マイル先
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Northwestern Medicine Oak Brook, Oak Brook · 9マイル先
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Hope and Healing Cancer Services, Hinsdale · 10マイル先
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
被験者募集中第3相
- Advocate Christ Medical Center, Oak Lawn · 9マイル先
- Hope and Healing Cancer Services, Hinsdale · 10マイル先
- Endeavor Health, Elmhurst · 10マイル先
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
被験者募集中第2相
- Hope and Healing Clinical Research, Hinsdale · 10マイル先
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Hinsdale · 10マイル先
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
被験者募集中第3相
- Affiliated Oncologists, LLC, Chicago Ridge · 10マイル先
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Hinsdale · 10マイル先
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- Loyola University Medical Center, Maywood · 5マイル先
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
被験者募集中第3相
- Hope and Healing Cancer Services, Hinsdale · 10マイル先
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- Affiliated Oncologists, LLC, Chicago Ridge · 10マイル先
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Hinsdale · 10マイル先
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Hinsdale · 10マイル先
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
被験者募集中第3相
- Northwestern Medicine Oak Brook, Oak Brook · 9マイル先
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- Elmhurst Hospital Nancy Knowles Cancer Center, Elmhurst · 10マイル先
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Rush MD Anderson Cancer Center at Rush Oak Park, Oak Park · 3マイル先
- Edward Hines Jr VA Hospital, Hines · 4マイル先
- Loyola University Medical Center, Maywood · 5マイル先
- 他2件
MYLUNG Consortium Part 3: Observational Study
被験者募集中観察研究
- Affiliated Oncologists, LLC, Chicago Ridge · 10マイル先
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Edward Hines Jr VA Hospital, Hines · 4マイル先
- Loyola University Medical Center, Maywood · 5マイル先
- Northwestern Medicine Oak Brook, Oak Brook · 9マイル先
- 他3件
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Loyola University Medical Center, Maywood · 5マイル先
- Northwestern Medicine Oak Brook, Oak Brook · 9マイル先
- Advocate Christ Medical Center, Oak Lawn · 9マイル先
- 他2件
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Edward Hines Jr VA Hospital, Hines · 4マイル先
- Loyola University Medical Center, Maywood · 5マイル先
- Northwestern Medicine Oak Brook, Oak Brook · 9マイル先
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Advocate Christ Medical Center, Oak Lawn · 9マイル先
- Advocate Outpatient Center - Oak Lawn, Oak Lawn · 9マイル先
- Advocate High Tech Medical Park, Palos Heights · 12マイル先
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
被験者募集中
- Edward Hines Jr. VA Hospital, Hines, IL, Hines · 4マイル先
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Hope and Healing Cancer Services, Hinsdale · 10マイル先
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Ciceroにおける他の研究
- 肺がん17件の研究
- 前立腺がん14件の研究
- がん（全種類）13件の研究
- 乳がん11件の研究
- 急性骨髄性白血病11件の研究
- 大腸癌10件の研究
- 膀胱癌8件の研究
- 悪性黒色腫7件の研究
- 心血管疾患7件の研究
- 転移性癌7件の研究
- 多発性骨髄腫6件の研究
- バーキットリンパ腫6件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。